.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA03_Melphalan.Melphalan_1 .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01A_AlkylatingAgents.L01AA03_Melphalan.Melphalan_1| name: | Melphalan_1 |
| ATC code: | L01AA03_1 | route: | oral |
| n-compartments | 1 |
Melphalan is an alkylating agent used in the treatment of multiple myeloma and ovarian cancer. It works by cross-linking DNA, thus inhibiting DNA and RNA synthesis and leading to cell death. It is still approved and in clinical use, particularly for hematological malignancies.
Pharmacokinetic parameters derived from adult patients after oral administration of melphalan for multiple myeloma.
Nath, CE, et al., & Earl, J (2010). Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British journal of clinical pharmacology 69(5) 484–497. DOI:10.1111/j.1365-2125.2010.03638.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/20573084
Mizuno, K, et al., & Vinks, AA (2018). Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation. Clinical pharmacokinetics 57(5) 625–636. DOI:10.1007/s40262-017-0581-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/28918602